GlioblastomaGLIORUNNCT07865195
Diffuse Gliomas in Reunion Island: Establishment of an Epidemiological, Clinical-biological and Socio-anthropological Cohorte
An observational study of Glioblastoma, run by Centre Hospitalier Universitaire de la Réunion at 1 site in Reunion.
Trial summary
To date, very little data exists on gliomas in the Réunion population, in terms of epidemiology, socio-cultural aspects, clinical or biological factors, and care pathways. However, the Réunion population is multicultural and highly cosmopolitan, experiencing rapid aging, and its socio-economic indicators are among the… Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Glioblastoma
- How many people
- 214 participants
- Where
- 1 siteReunion
- Study dates
- 7 Apr 2025to 7 Nov 2028
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: person with glioma at La Réunion Island
Who may be able to join
- Quantitative study (retrospective and prospective components):
- Patients aged 18 and over:
- With a histological diagnosis of incident diffuse glioma since January 1, 2018
- Residing in Réunion at the time of diagnosis,
- Having been informed about the study procedures
- Having agreed to participate in the study
Show all 13Show fewer
- Socio-anthropological study (prospective component):
- Patients:
- Meeting the inclusion criteria for the prospective quantitative study and agreeing to participate in the qualitative component,
- Speaking French. • Able to participate in a face-to-face interview
- Healthcare Professional:
- Professionals involved in the care of patients with brain tumors (medical, paramedical, social care, support care, etc.) who have agreed to participate in the study
- The healthcare professionals concerned will be general practitioners, neurosurgeons, neurologists, radiation oncologists, medical oncologists, home healthcare physicians, palliative care physicians, pathologists, nurses responsible for diagnosis and follow-up, psychologists, social workers, and dietitians.
Who cannot join
- Regarding the quantitative study:
- Patient:
- Refusing to participate in the quantitative study Having a recurrent diffuse glioma Person deprived of their liberty and judgment by judicial or administrative decision, and person subject to a legal protection measure: guardianship or curatorship, under judicial protection, under legal guardianship, etc.)
- Regarding the socio-anthropological study:
- Patient:
- Refusing to participate in the qualitative study Does not speak French Having serious somatic or mental health problems incompatible with the interview Healthcare professionals: Refusing to participate in the study
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Reunion1 site, 1 recruiting
- Recruiting
Mélanie BEGORRE
Saint-Pierre, 97410
CHU La Réunion DRCI, 0262359000, promotion.drci@chu-reunion.fr
About this study
To date, very little data exists on gliomas in the Réunion population, in terms of epidemiology, socio-cultural aspects, clinical or biological factors, and care pathways. However, the Réunion population is multicultural and highly cosmopolitan, experiencing rapid aging, and its socio-economic indicators are among the most pessimistic of all French departments. Furthermore, the healthcare services available on the island are less comprehensive than those in metropolitan France (Insee 2018). Finally, the management of patients with gliomas, particularly high-grade gliomas, remains very complex, with significant medical and social challenges (supportive care, end-of-life care, etc.). Healthcare professionals agree that these specialized facilities are insufficient to meet the care needs in Réunion (post-acute care, palliative care units, supportive care, etc.).
GlioRun is a retrospective and prospective mixed-methods cohort study, combining epidemiological and socio-anthropological approaches, which aims to produce data to improve care and the experiences of patients and their relatives on Reunion Island, and reduce the number of medical evacuations to mainland France.
- Conditions
- Glioblastoma
- Medical subject headings
- Glioblastoma
What is being measured
The primary outcome is the main question the study is designed to answer.
Distribution of sociodemographic characteristics at diagnosis
Distribution of age at diagnosis (years), sex (male/female), ethnicity, and socioeconomic indicators among patients diagnosed with diffuse glioma in Réunion Island
Measured: two years
Secondary outcomes (3)
Clinical presentation of diffuse gliomas at diagnosis
Clinical characteristics at diagnosis including presenting symptoms, performance status (e.g., Karnofsky Performance Status score), tumor location, and initial treatment modalities
Measured: 2 years
Molecular characteristics of diffuse gliomas
Tumor molecular markers including IDH mutation status, 1p/19q codeletion status, and MGMT promoter methylation status assessed at diagnosis
Measured: inclusion
Histopathological classification of diffuse gliomas
Histopathological classification of tumors according to the WHO classification of central nervous system tumors at diagnosis
Measured: inclusion
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Oct 2026
- Study start7 Apr 2025
- Primary completion7 Apr 2028 (estimated)
- Study completion7 Nov 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for GlioblastomaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Enrolment
- 214 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Centre Hospitalier Universitaire de la Réunion
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07865195
- Sponsor's protocol ID
- 2023/CHU/39
- Acronym
- GLIORUN
- Status last verified
- Oct 2026
- First submitted
- 16 Mar 2026
- Last updated
- 8 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 8 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Diffuse Gliomas in Reunion Island: Establishment of an Epidemiological, Clinical-biological and Socio-anthropological Cohorte
- ClinicalTrials.gov ID
- NCT07865195
- Acronym / sponsor ID
- GLIORUN / 2023/CHU/39
- Conditions
- Glioblastoma
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 214 participants (estimated)
- Lead sponsor
- Centre Hospitalier Universitaire de la RéunionUniversity, hospital or other
- Study start
- 7 Apr 2025 (actual)
- Primary completion
- 7 Apr 2028 (estimated)
- Study completion
- 7 Nov 2028 (estimated)
- First posted
- 8 Oct 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
To date, very little data exists on gliomas in the Réunion population, in terms of epidemiology, socio-cultural aspects, clinical or biological factors, and care pathways. However, the Réunion population is multicultural and highly cosmopolitan, experiencing rapid aging, and its socio-economic indicators are among the most pessimistic of all French departments. Furthermore, the healthcare services available on the island are less comprehensive than those in metropolitan France (Insee 2018). Finally, the management of patients with gliomas, particularly high-grade gliomas, remains very complex, with significant medical and social challenges (supportive care, end-of-life care, etc.). Healthcare professionals agree that these specialized facilities are insufficient to meet the care needs in Réunion (post-acute care, palliative care units, supportive care, etc.).
GlioRun is a retrospective and prospective mixed-methods cohort study, combining epidemiological and socio-anthropological approaches, which aims to produce data to improve care and the experiences of patients and their relatives on Reunion Island, and reduce the number of medical evacuations to mainland France.
Study design
- Observational model
- Cohort
- Time perspective
- Cross-sectional
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- person with glioma at La Réunion Island
Key inclusion criteria (13 listed)
- With a histological diagnosis of incident diffuse glioma since January 1, 2018
- Residing in Réunion at the time of diagnosis,
- Having been informed about the study procedures
- Having agreed to participate in the study
- Meeting the inclusion criteria for the prospective quantitative study and agreeing to participate in the qualitative component,
Key exclusion criteria (6 listed)
- Refusing to participate in the quantitative study Having a recurrent diffuse glioma Person deprived of their liberty and judgment by judicial or administrative decision, and person subject to a legal protection measure: guardianship or curatorship, under judicial protection, under legal guardianship, etc.)
- Refusing to participate in the qualitative study Does not speak French Having serious somatic or mental health problems incompatible with the interview Healthcare professionals: Refusing to participate in the study
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Distribution of sociodemographic characteristics at diagnosis
Time frame: two years
Distribution of age at diagnosis (years), sex (male/female), ethnicity, and socioeconomic indicators among patients diagnosed with diffuse glioma in Réunion Island
3 secondary outcomes
Clinical presentation of diffuse gliomas at diagnosis
Time frame: 2 years
Molecular characteristics of diffuse gliomas
Time frame: inclusion
Histopathological classification of diffuse gliomas
Time frame: inclusion
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 Oct 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Glioblastoma
Active, not recruitingPhase 3
EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma
Glioblastoma
RecruitingPhase 3
Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of Care
Glioblastoma
RecruitingPhase 1/2
Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment
Recurrent Glioblastoma, IDH-Wildtype, Recurrent MGMT-Methylated Glioblastoma
Active, not recruitingPhase 1
Oral Gallium Maltolate for the Treatment of Relapsed and Refractory Glioblastoma
Glioblastoma
RecruitingPhase 1/2
PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications
Glioma, Medulloblastoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Glioblastoma, run by Centre Hospitalier Universitaire de la Réunion at 1 site in Reunion.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 13 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 8 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Reunion. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Distribution of sociodemographic characteristics at diagnosis (time frame: two years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Oct 2026.